全肺导向抗毒蕈碱治疗改善慢阻肺患者小气道功能障碍
该文指出,将吸入治疗定向分布至病变肺区域可改善患者肺功能。小气道疾病应被视为可治疗特质并在临床中主动筛查,从而针对该区域进行治疗。小气道功能障碍在慢阻肺患者中患病率为50%至90%,与症状相关,且常早于常规肺功能异常。
要点
- 小气道疾病是慢阻肺关键特征,常先于肺气肿出现。
- 小气道功能障碍在慢阻肺患者中患病率为50%至90%。
- 小气道功能障碍应被视为可治疗特质并主动筛查。
核心结论
- 全肺导向抗毒蕈碱治疗可改善慢阻肺患者小气道功能障碍。
- 小气道疾病应被视为可治疗特质并在临床中主动寻找以指导靶向治疗。
主要发现
- 小气道功能障碍在慢阻肺患者中患病率为50%至90%,并与症状相关。
- 小气道功能障碍通常早于常规肺功能异常出现。
- 小气道功能障碍导致患者生活质量负担和疾病急性加重。
临床怎么用
- 临床中应主动筛查小气道功能障碍,将其作为可治疗特质进行靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Directed distribution of inhaled therapy to diseased lung regions improves patient lung function. Small airway disease should be considered a treatable trait and actively sought in the clinic, leading to targeting therapeutic treatment to this region. https://bit.ly/4oHAwGM Small airway disease is a key feature of COPD that often precedes emphysema, with the small airways representing a major site of airflow limitation [1]. The prevalence of small airway dysfunction (SAD) ranges from 50% to 90% in COPD patients, and correlates with symptoms [2]. SAD is usually well-established before conventional spirometry is abnormal [3], and contributes to patient quality-of-life burden [4] and disease exacerbations [5].
引用
- Usmani OS, Toumpanakis D, Meah S, et al. Whole lung directed anti-muscarinic therapy improves small airway dysfunction in COPD patients. Eur Respir J. 2026. PMID: 41309266. doi:10.1183/13993003.01326-2025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。